H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating

On May 28, H.C. Wainwright analyst Yi Chen initiated coverage of NeuroPace, Inc. (NASDAQ:NPCE) with a Buy rating and a price target of $18. The rating comes after the company released preliminary results for one-year data in NAUTILUS study.

On May 27, the company announced key results from its NAUTILUS study, the first clinical trial evaluating its RNS system for drug-resistant idiopathic generalized epilepsy. The study met its primary safety endpoint at 12 weeks post-implant, demonstrating a low rate of serious adverse events and reinforcing the device's established safety profile. The analyst noted that the system demonstrated significant seizure reduction in the clinical stage.

Moreover, NeuroPace, Inc. (NASDAQ:NPCE) delivered robust results for the fiscal first quarter of 2025. The revenue grew more than 24% year-over-year to $22.52 million and surpassed expectations by $676,490, whereas the EPS of $-0.21 also exceeded consensus by $0.03. The analyst said that the stock has appreciated over 150% during the past year and the recent data from the study presents an attractive entry point for investors.

NeuroPace Inc. (NASDAQ:NPCE) is a commercial-stage medical device company that develops the RNS system. RNS system is an implantable brain-responsive device designed to reduce or prevent seizures in people with drug-resistant epilepsy.

While we acknowledge the potential of NPCE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NPCE and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Most Promising New Technology Stocks According to Analysts and 12 Best Growth Stocks to Buy and Hold for the Long Term.

Disclosure: None.